Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 5/20 | 0.41 |
| ▸ | CDK8 | P49336 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313863 | 1.00 | DPP4 (0.47) | DPP4FDPSCCNCCDK8CA12 | |
| SCHEMBL29446160 | 1.00 | DPP4 (0.47) | DPP4FDPSCCNCCDK8CA12 | |
| SCHEMBL12090835 | 0.85 | DPP4 (0.44) | DPP4FDPSCCNCCDK8CA12 | |
| SCHEMBL22612208 | 0.83 | MAPT (0.43) | DPP4CCNCCDK8CA12CA1 | |
| SCHEMBL22612206 | 0.83 | MAPT (0.43) | DPP4CCNCCDK8CA12CA1 | |
| SCHEMBL4144972 | 0.82 | THRB (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4144963 | 0.82 | THRB (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31521738 | 0.81 | CNKSR1 (0.44) | DPP4CCNCCDK8CA12CA1 | |
| SCHEMBL30509249 | 0.81 | CNKSR1 (0.44) | DPP4CCNCCDK8CA12CA1 | |
| SCHEMBL4711384 | 0.81 | CNKSR1 (0.44) | DPP4CCNCCDK8CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-06 | — | — | US | disclosed |
| EP-3283642-B1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RES CENTER HOLDING B V (NL) | 2023-10-11 | — | — | EP | disclosed |
| CN-114592061-A | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-107567503-B | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2022-02-24 | — | — | US | disclosed |
| US-11208696-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2021-12-28 | — | — | US | disclosed |
| US-20190211401-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-07-11 | — | — | US | disclosed |
| US-9856258-B2 | (5,6-dihydro)pyrimido[4,5-E]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2018-01-02 | — | — | US | disclosed |
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| WO-2016166255-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2016-10-20 | — | — | WO | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | DHFR, CYP2D6, DPYD | DPP4 1313/4885FDPS 1113/4885CCNC 29/4885 |
| US-12054784-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | DPP4 3448/4885FDPS 2733/4885CCNC 881/4885 |
| US-20220056540-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | TTBK1, CTNNB1, TTK | DPP4 3448/4885FDPS 2733/4885CCNC 881/4885 |
| US-20190211401-A1 | PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY | TTBK1, CTNNB1, TTK | DPP4 3448/4885FDPS 2733/4885CCNC 881/4885 |
| US-11208696-B2 | Prognostic biomarkers for TTK inhibitor chemotherapy | TTBK1, CTNNB1, TTK | DPP4 3448/4885FDPS 2733/4885CCNC 881/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | DPP4 2706/4885FDPS 3276/4885CCNC 768/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | DPP4 2934/4885FDPS 3196/4885CCNC 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.